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TIMP-2 Mediated Inhibition of Angiogenesis:
An MMP-Independent Mechanism
of degrading all components of the extracellular matrix
(Coussens et al., 2002). In addition to transcriptional
control and activation of zymogen forms, endogenous
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proforms of MMP family members and regulate their
cell surface activation (Baker et al., 2002; Jiang et al.,
2002). The requirement of MMP activity for tumor cellSummary
invasion, metastasis formation, and angiogenesis is
demonstrated by TIMP inhibition of these processes,Tissue inhibitors of metalloproteinases (TIMPs) sup-
and led to the development of synthetic MMP inhibitorspress matrix metalloproteinase (MMP) activity critical
for potential therapeutic application (Coussens et al.,for extracellular matrix turnover associated with both
2002; Jiang et al., 2002).physiologic and pathologic tissue remodeling. We
In addition to their MMP inhibitory activity, it is nowdemonstrate here that TIMP-2 abrogates angiogenic
widely appreciated that TIMPs have pluripotential ef-factor-induced endothelial cell proliferation in vitro
fects on cell growth, apoptosis, and differentiationand angiogenesis in vivo independent of MMP inhibi-
(Baker et al., 2002; Jiang et al., 2002). TIMP-1 is reportedtion. These effects require 31 integrin-mediated
to have erythroid-potentiating activity, inhibit B cell apo-binding of TIMP-2 to endothelial cells. Further, TIMP-2
ptosis, and promote B cell differentiation (Guedez et al.,induces a decrease in total protein tyrosine phospha-
1998, 2001a; Jiang et al., 2002). In contrast, TIMP-3tase (PTP) activity associated with1 integrin subunits
inhibits TNF- converting enzyme and induces apopto-as well as dissociation of the phosphatase SHP-1 from
sis in several cell culture systems including rat vascular1. TIMP-2 treatment also results in a concomitant
smooth muscle cells, as well as tumor cell lines (Bakerincrease in PTP activity associated with tyrosine ki-
et al., 1999). TIMP-4 reportedly stimulates growth ofnase receptors FGFR-1 and KDR. Our findings estab-
human breast cancer xenografts following systemic ad-lish an unexpected, MMP-independent mechanism for
ministration by intramuscular gene delivery (Jiang etTIMP-2 inhibition of endothelial cell proliferation in
al., 2001). TIMP-2 has been reported to have erythroid-vitro and reveal an important component of the antian-
potentiating activity, stimulate quiescent cell prolifera-giogenic effect of TIMP2 in vivo.
tion, function as a metanephric mesenchymal growth
factor, and inhibit FGF-stimulated endothelial cellIntroduction
growth (Baker et al., 2002; Jiang et al., 2002; Murphy et
al., 1993). The effects of TIMPs on cell proliferation or
In the adult mammalian organism, the formation of new
cell death may be mediated indirectly by inhibition/acti-
vascular sprouts from existing capillaries occurs in re- vation of selective MMPs and in most examples are
sponse to a variety of pathologic stimuli and is referred limited to in vitro systems. Alternatively, it has been
to as the process of angiogenesis (Carmeliet, 2000; Car- proposed that TIMPs interact with specific cell surface
meliet and Jain, 2000). Initiation of an angiogenic re- receptors in order to modulate cell proliferation and/or
sponse is the result of local changes in the balance of programmed cell death (Murphy et al., 1993), but no
proangiogenic factors and angiogenesis inhibitors, i.e., such receptor has been reported to date.
the angiogenic switch (Hanahan and Folkman, 1996). A number of endogenous inhibitors of angiogenesis
Angiogenesis is differentially regulated from the process have been shown to mediate their antiangiogenic effects
of embryonic vascular development known as vasculo- by direct or indirect interactions with integrins. These
genesis (Carmeliet, 2000; Carmeliet and Jain, 2000). include endostatin, thrombospondin, and tumstatin. The
Therapeutic manipulation of the angiogenic response relationship between regulation of MMP activity and in-
holds promise for novel treatment strategies in a variety tegrin receptors is complex. The activity of MMPs has
of human disease states, including cancer, arthritis, and been implicated in generating a variety of angiogenesis
cardiovascular disease (Carmeliet and Jain, 2000). inhibitors, as well as unmasking of cryptic sites in the
Matrix metalloproteinases (MMPs) are a family of zinc- extracellular matrix (ECM) that can modulate cell prolif-
dependent endopeptidases that collectively are capable eration and/or migration through interaction with integ-
rin receptors (Giannelli et al., 1997; Stupack and Che-
resh, 2002). Conversely, integrins have been implicated*Correspondence: sstevenw@mail.nih.gov
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both in modulating endothelial cell MMP production and
localization (Brooks et al., 1996; Sugiura and Berditchev-
ski, 1999). However, to date no direct interaction be-
tween members of the TIMP family and integrins has
been demonstrated.
The goals of the current study are to (1) demonstrate
that TIMP-2 inhibition of human microvascular endothe-
lial cell (hMVEC) proliferation both in vitro and in vivo
can be dissociated from MMP inhibitory activity; (2) de-
fine the cell surface receptor that mediates these inhibi-
tory effects of TIMP-2 on endothelial cell proliferation;
and (3) describe the mechanism of TIMP-2 inhibition of
growth factor stimulation. To accomplish these goals,
we utilize recombinant TIMP-2 and a mutant form of
TIMP-2, referred to as AlaTIMP-2, which contains a
single alanine residue appended to the amino-terminal
cysteine of the wild-type TIMP-2 which results in loss
of MMP inhibitor activity (Hoegy et al., 2001; Wingfield et
al., 1999). Our findings indicate that TIMP-2 cell surface
binding to hMVECs, mediated by 31 integrin, results
in negative regulation of growth factor activation that
Figure 1. TIMP-2 Suppression of hMVEC Proliferation Is Indepen-requires the activity of the PTP SHP-1.
dent of Anti-MMP Activity
(A) Effects of MMP inhibitors on FGF-2-induced proliferation of
Results hMVECs. Statistical significance is indicated (** p  0.01).
(B) Dose-dependent suppression of FGF-2- or VEGF-A-induced
hMVEC proliferation. -TIMP-2FGF-2; -TIMP-2VEGF-A;TIMP-2 Suppresses hMVEC Proliferation In Vitro
-AlaTIMP-2VEGF-A.Primary hMVEC cultures are maintained for 24 hr in the
absence of growth factor supplements to allow synchro-
nization and growth arrest (G1/G0). These cultures are
to previous reports by our laboratory for TIMP-2 wherethen treated with purified recombinant TIMP-2 prior to
the IC50 for inhibition of cell growth was determinedgrowth factor stimulation. We also treated endothelial
as 100 nM TIMP-2 (Hoegy et al., 2001; Murphy et al.,cells with AlaTIMP-2, a null-MMP inhibitor form of
1993).TIMP-2, that contains a single alanine residue appended
to the amino-terminal cysteine of the wild-type TIMP-2
which results in loss of MMP inhibitor activity as pre- TIMP-2 Binding to hMVECs Does Not Antagonize
Angiogenic Factor Bindingviously reported (Hoegy et al., 2001; Wingfield et al.,
1999). Following stimulation with either FGF-2 or One possible mechanism for the observed effects of
TIMP-2 on hMVEC proliferation is that TIMP-2 binds toVEGF-A for 24 hr, endothelial cell proliferation is deter-
mined by analysis of cell number, as previously de- angiogenic factor receptors and/or interferes with FGF-2
or VEGF-A binding and activation of their cognate recep-scribed (Hoegy et al., 2001). The results of these initial
experiments clearly demonstrate that TIMP-2 inhibits tors. TIMP-3 has been recently reported to inhibit
VEGF-A-induced endothelial cell growth through antag-hMVEC proliferation in response to FGF-2 or VEGF-A
stimulation in vitro (Figure 1). TIMP-2 or AlaTIMP-2 onism of VEGF receptor-2 (Qi et al., 2003). To determine
if TIMP-2 binds directly to hMVECs, and if this interactionpretreatment inhibits hMVEC proliferation in response to
FGF-2 stimulation to the levels observed in unstimulated interferes with binding of angiogenic factors to cognate
receptors on hMVECs, we utilize a competitive bindingcultures (Figure 1A). A synthetic broad-spectrum MMP
inhibitor (BB-94, 100 nM), TIMP-1 (Murphy et al., 1993), approach. Specific binding of 125I-TIMP-2 to nonstimu-
lated hMVECs is both saturable and reversible, with aor AlaTIMP-1 (null inhibitor form of TIMP-1) did not
alter endothelial cell proliferation, demonstrating the KD 0.9 0.12 109 M (R2 0.999) and approximately
75,000 sites per cell (Figure 2A). These data are similar tospecificity of TIMP-2 for this effect. In addition, this in-
hibitory effect on cell proliferation requires free TIMP-2, previous reports on TIMP-2 cell binding characteristics
(Emmert-Buck et al., 1995; Hoegy et al., 2001).as the pro-MMP-2/TIMP-2 complex did not inhibit
hMVEC proliferation as previously reported (Murphy et Binding of 125I-TIMP-2 (10 nM) to hMVECs is competed
by addition of 100-fold excess unlabeled AlaTIMP-2al., 1993).
The potent antiproliferative activity of AlaTIMP-2 (Figure 2B). Competition binding experiments reveal that
TIMP-2 binding to microvascular endothelial cells is notand lack of inhibition by other MMP inhibitors in these
in vitro cultures demonstrate that the effect of TIMP-2 altered by addition of FGF-2, anti-FGFR-1-blocking anti-
bodies, VEGF-A, or anti-VEGFR-2-blocking antibodieson hMVEC proliferation is independent of anti-MMP ac-
tivity. Combination of BB-94 with TIMP-2 or AlaTIMP-2 (Figure 2B). Both pericellular and cell surface-associ-
ated MMPs represent other putative TIMP-2 bindingdid not alter the inhibitory effects of TIMP-2 or Ala
TIMP-2 on hMVEC proliferation. The inhibitory activity sites. Anti-MT1-MMP antibodies did not interfere with
TIMP-2 binding to the hMVEC surface (Figure 2B), inof TIMP-2 and AlaTIMP-2 are concentration depen-
dent for both FGF-2- and VEGF-A-stimulated hMVEC agreement with previous observations on TIMP-2 bind-
ing to human tumor cells (Hoegy et al., 2001). In addition,proliferation (Figure 1B). These results are comparable
TIMP-2 Inhibition of Angiogenesis
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Figure 2. TIMP-2 Binding to hMVEC Is Not Antagonized by FGF-2
or VEGF-A
(A) 125I-TIMP-2 binding to hMVEC cells is dose dependent, saturable,
and reversible. Curve fit analysis (GraphPad, Prism Software) reveals
Figure 3. 31 Integrin Is a TIMP-2 Receptora KD  0.9  0.12  109 M (R2  0.999).
(A) Competition binding of 125I-AlaTIMP-2 (10 nM) to hMVEC by(B) Angiogenic factors and RTK-blocking antibodies do not compete
anti-integrin antibodies. Competition binding experiments were per-for 125I-TIMP-2 or 125I-AlaTIMP-2 binding to hMVECs. Statistical
formed in the presence of anti- integrin subunit antibodies (leftsignificance is indicated (** p  0.01).
image) or anti- integrin subunit antibodies (right image). Statistical(C) TIMP-2 does not interfere with heparin-induced FGF-2 dimeriza-
significance is indicated (* p  0.05).tion. FGF-2 dimers were separated by SDS-PAGE and quantified
(B) In vitro binding of TIMP-2 to purified integrin heterodimers. Sta-by autoradiography as previously described (Perollet et al., 1998).
tistical significance is indicated (* p  0.05; **p  0.01).
(C) Analysis of TIMP-2 immunoprecipitates. Cell lysates from un-
treated (control) or AlaTIMP-2-treated hMVECs were immunopre-
use of 125I-AlaTIMP-2, instead of 125I-TIMP-2 reduced cipitated using anti-TIMP-2 antibody and analysis for integrin sub-
this background and increased the specific binding frac- units was performed by Western blotting. Whole-cell lysates (WCL)
tion to greater than 90% (Figure 3A). were used as positive controls.
(D) TIMP-2 binding to 31 alters association with SHP-1 andInteraction of FGF-2 with its receptors is complex,
HSP60. Both anti-3 and anti-1 immunoprecipitates from hMVECsinvolving both heparin-induced ligand dimerization and
were analyzed by Western blot for the association of SHP-1 andsubsequent receptor binding, as illustrated by platelet
HSP60.
factor-4 (PF-4) inhibition of angiogenesis (Perollet et al., (E) 1-deficient murine embryonic fibroblasts are resistant to TIMP-2
1998). To determine if TIMP-2 alters heparin-induced suppression of PDGF-induced proliferation. Both GD25 1-deficient
FGF-2 dimerization, we utilized a previously described murine embryonic fibroblasts (left image) and GD25-1A cells with
reconstituted 1 expression (right image) were treated with PDGFcrosslinking technique (Perollet et al., 1998). These ex-
(100 ng/ml) alone, AlaTIMP-2 (100 nM) alone or both AlaTIMP-2periments using 125I-FGF-2, heparin, and TIMP-2 show
and PDGF. Cell proliferation assays were conducted following 24that TIMP-2 did not diminish the heparin-dependent
hr incubation (**p  0.01).
FGF-2 dimer formation, as determined by chemical
crosslinking, SDS-PAGE, and autoradiography (Figure
2C). Collectively, these competitive binding studies sug- zation of TIMP-2 with1 integrin subunits in A549 human
gest that TIMP-2 does not bind directly to FGFR-1, KDR, lung cancer cells (G. Gonzalez-Avila and W.G.S.-S., un-
or MT1-MMP, and that TIMP-2 does not disrupt FGF- published data). These observations led us to screen
2-heparin interactions that facilitate receptor binding. anti-integrin antibodies for competition with TIMP-2
binding to hMVECs. We utilized a series of anti-integrin
antibodies to compete for binding of 125I-AlaTIMP-2 to31 Integrin Is a TIMP-2 Receptor
To identify putative TIMP-2 receptors on hMVECs we hMVEC (Figure 3A). 125I-AlaTIMP-2 was utilized in these
experiments to reduce potential background fromutilized the same competitive binding approach de-
scribed above. Preliminary data demonstrate colocali- TIMP-2 binding to MMP active sites (Hoegy et al., 2001).
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Of the anti- subunit blocking antibodies tested only and angiogenic factor stimulation of hMVECs. The loss
of TIMP-2 inhibitory effects in GD25 cell indicates thatanti-1 antibodies demonstrated statistically significant
inhibition of TIMP-2 binding to hMVECs (Figure 3A). Sim- TIMP-2 interaction with 1 integrin is required for inhibi-
tion of angiogenic factor-induced cell proliferation.ilarly, only the two anti-3 subunit-blocking antibodies
reduced TIMP-2 binding in a statistically significant
manner (Figure 3A). These results suggest that TIMP-2 TIMP-2 Suppression of hMVEC Proliferation
binds to 31 integrin on the surface of hMVECs. Is PTP-Dependent
To confirm this interaction and the specificity of FGF-2 and VEGF-A stimulation of endothelial cell growth
TIMP-2 for 31, we examined the direct interaction are initiated by interaction with their cognate receptors,
of TIMP-2 with 11, 31, and 51 in vitro. Control FGFR and VEGFR, both members of the receptor tyro-
experiments demonstrate that the “natural” macromo- sine kinase family (RTK) (Carmeliet, 2000). RTK activa-
lecular ligands, collagen IV, laminin-1, and fibronectin, tion is evidenced by autophosphorylation of specific
respectively, bind directly to these immobilized integrins tyrosine residues within the homodimer subunits and
in vitro. Specific binding of 125I-AlaTIMP-2 to immobi- this autophosphorylation/activation can be reversed by
lized integrins in vitro demonstrates a selective interac- protein tyrosine phosphatase (PTP) activities (Tonks and
tion of AlaTIMP-2 with 31 that is not observed with Neel, 2001). Orthovanadate is well characterized as a
either 11 or 51 (Figure 3B). The selective binding selective, but not universal, inhibitor of PTP activities
of 125I-AlaTIMP-2 to 31 is competed by unlabeled (Brautigan and Shriner, 1988; Lau et al., 1989). We exam-
AlaTIMP-2, laminin-1, and inhibited in the presence of ine the general requirement for PTP activity in mediating
EDTA (10 mM). In addition, direct immunoprecipitation the TIMP-2 effect on FGF-2 and VEGF-A stimulation of
of TIMP-2 from hMVEC lysates reveals the presence of hMVEC proliferation using sodium orthovanadate as a
both 1 and 3 subunits in complex with TIMP-2, but PTP inhibitor. Alone sodium orthovanadate (1 	M) pre-
other  or  integrin subunits are either not detected or treatment of hMVECs does not alter the basal growth
present at very low levels (Figure 3C). These findings or the FGF-2-induced mitogenic response of these cells
again demonstrate the selective binding of TIMP-2 to following 24 hr incubation (Figure 4A). However, ortho-
31. Characterization of separate 3 and 1 integrin vanadate does completely abrogate the inhibitory effect
subunit immunoprecipitates from hMVECs, with and of TIMP-2 on FGF-2- or VEGF-A-induced proliferation
without TIMP-2 treatment, demonstrates that TIMP-2 of hMVECs (Figure 4A). In contrast, pretreatment of
binding results in loss of HSP60 and SHP-1 association hMVECs with okadaic acid, which preferentially inhibits
with these receptor subunits (Figure 3D). This finding is serine/threonine phosphatase activities, did not reverse
confirmed in direct in vitro binding experiments in which TIMP-2 suppression of proliferative responses to either
HSP60 competes with 125I-AlaTIMP-2 binding to 31. FGF-2 or VEGF-A. These findings suggest that PTP ac-
The observation that TIMP-2 binding to 31 results tivity mediates the TIMP-2 inhibition of both FGF-2- and
in decrease SHP-1 suggests that propagation of the VEGF-A-stimulated proliferation of hMVECs.
TIMP-2 signal from the extracellular binding domain of We next determine the effect of TIMP-2 on the activa-
this integrin alters association of proteins (SHP-1) known tion/phosphorylation status of FGFR and VEGFR in
to bind to intracellular sites on the cytoplasmic tails of hMVECs. Quantitative polymerase chain reaction (PCR)
the 31 integrin subunits. experiments show that FGFR-1 is the principal receptor
produced by hMVECs, and that FGFR-1 or VEGFR-2
transcript levels are not influenced by TIMP-2 treatment1 Null Fibroblast Proliferation Is Not
Suppressed by TIMP-2 (Tartaglia et al., 2001). Previous studies have also dem-
onstrated that VEGFR-2 (KDR, human homolog of Flk-1)To determine the functional role of 31 in mediating
the inhibitory effect of TIMP-2 on cell proliferation, we is specifically responsible for mediating the mitogenic
effects of VEGF-A (Carmeliet and Jain, 2000). Thesestudied the effects of TIMP-2 on PDGF-induced prolifer-
ation of 1 null GD25 fetal murine fibroblasts, as well as immunoprecipitation experiments are conducted fol-
lowing TIMP-2 pretreatment (15 min) and subsequentGD25-1A cells that have reconstituted 1 expression.
These cells have been previously characterized in sev- brief growth factor stimulation (5 min) in order to exam-
ine early, immediate effects on RTK phosphorylation.eral laboratories and inactivation of 1 in the homozy-
gous mutant suppresses surface expression of 3, 5, Orthovanadate treatment of hMVEC without subsequent
growth factor stimulation results in a slight increase inand 6 (Fassler et al., 1995; Wennerberg et al., 2000).
GD25 and GD25-1A cells respond to PDGF stimulation FGFR-1 and KDR phosphorylation similar to previous
reports on KDR phosphorylation (Guo et al., 2000), that(100 ng/mL) with approximately 2-fold increase in cell
numbers over 24 hr (Figure 3E) and we have previously is inhibited by TIMP-2, but did not alter the proliferative
response of hMVECs under basal conditions (Figure 4A).demonstrated that TIMP-2 inhibits the proliferative re-
sponse to PDGF in A549 human lung adenocarcinoma Treatment with FGF-2 or VEGF-A alone, results in a
6-fold increase in FGFR-1 or KDR phosphorylation overcells (Hoegy et al., 2001). The proliferative response of
GD25 cells to PDGF was not inhibited by TIMP-2 pre- basal levels (Figure 4B). TIMP-2 or AlaTIMP-2 treat-
ment prior to FGF-2 or VEGF-A stimulation results in atreatment (Figure 3E). In contrast, GD25-1A cells pre-
treated with TIMP-2, prior to PDGF stimulation, show a significant decrease of 50%–60% in cognate receptor
phosphorylation (Figure 4B). This effect of TIMP-2 onsignificant reduction in proliferation to levels statistically
indistinguishable from that observed in unstimulated FGFR-1 and KDR phosphorylation is dose dependent.
In TIMP-2-treated hMVECs orthovanadate completelycells (Figure 3E). These data with the GD25-1A cells are
similar to those observed following TIMP-2 pretreatment restores RTK phosphorylation to levels comparable
TIMP-2 Inhibition of Angiogenesis
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Figure 4. TIMP-2 Suppression of Endothelial
Cell Proliferation Is Dependent on Protein Ty-
rosine Phosphatase SHP-1 Activity
(A) Orthovanadate reverses TIMP-2 effect on
FGF-2- and VEGF-A-stimulated endothelial
cell proliferation. Statistical significance is in-
dicated (** p  0.01).
(B) TIMP-2 treatment reduces FGFR-1 and KDR
phosphorylation/activation. Anti-FGFR-1 (left
image) or KDR (right image) immunoprecipi-
tates were resolved by SDS-PAGE and West-
ern blotted with antiphosphotyrosine resi-
dues (PY-20), anti-FGFR-1 (H-76, loading
control), or anti-KDR antibody (loading con-
trol). Orthovanadate treatment under basal
conditions did not increase RTK phosphory-
lation (as indicated by/). Anti-FGFR-1 and
anti-KDR immunoprecipitates were also ana-
lyzed for SHP-1 association by Western blot-
ting. Integrated density values (and ratios) are
for the blot shown.
(C) Dominant-negative SHP-1 expression re-
verses TIMP-2 suppression of hMVEC prolif-
eration.
with angiogenic factors alone (Figure 4B). TIMP-2 or altered by TIMP-2, angiogenic factor, or orthovanadate
AlaTIMP-2 treatment results in a rapid (less than 5 min), treatment of hMVECs. Again these experiments were
MMP-independent decrease in FGFR-1 or KDR phos- conducted following TIMP-2 treatment and brief (5 min)
phorylation that is reversed by orthovanadate. This find- angiogenic factor stimulation to focus on early events.
ing indicates that TIMP-2 and AlaTIMP-2 inhibition of SHP-1 is associated with the FGFR-1 or KDR complex
hMVEC proliferation is mediated by PTP activity. under basal conditions, as evidenced by coprecipitation
(Figure 4B). FGF-2 or VEGF-A treatment alone results
in an 40% decrease in this interaction consistent withTIMP-2 Modulates Association of SHP-1
the observed increase in FGFR-1 and KDR phosphoryla-with RTKs in hMVECs
tion upon ligand binding (Figure 4B). TIMP-2 treatmentThe Src homology 2 (SH2) containing protein-tyrosine
prior to FGF-2 or VEGF-A stimulation enhances the as-phosphatases (SHPs) have been shown to interact with
sociation of SHP-1 with the FGFR-1 and KDR complexesmultiple growth factor receptors including tyrosine ki-
to levels observed in unstimulated hMVECs or slightlynase receptors, cytokine receptors, and immune com-
greater (Figure 4B). In addition, inactivation of the PTPplex receptors (Guo et al., 2000; Keilhack et al., 1998).
activity by inclusion of orthovanadate does not disruptWe recently reported that TIMP-2 inhibition of EGF-stim-
SHP-1 interaction with FGFR-1 or KDR, suggesting thatulated proliferation of A549 human tumor cells is medi-
these interactions are dependent on SH2-domain inter-ated by SHP-1 suppression of EGFR activation (Hoegy
actions and not the active site of the phosphatase. Theet al., 2001). In addition, tumor necrosis factor- (TNF-)
TIMP-2-induced association of SHP-1 with FGFR-1 orsuppression of endothelial cell proliferation in response
KDR in the presence of angiogenic factors, is similar toto VEGF or EGF stimulation requires SHP-1 activity (Guo
previous reports demonstrating SHP-1 association withet al., 2000). Based on these reports, we examine the
KDR during TNF- inhibition of endothelial cell prolifera-role of SHP-1 in mediating the suppressive effect of
tion (Guo et al. 2000), suggesting that TIMP-2 may evokeTIMP-2 on hMVEC proliferation.
a similar mechanism in suppression of FGF-2- or VEGF-Our initial experiments determine if SHP-1 associates
A-stimulated hMVEC proliferation.with the FGFR-1 and KDR complexes in a similar fashion
to that reported for EGFR, and if this association is To confirm the functional role of SHP-1 in suppression
Cell
176
Table 1. Protein Tyrosine Phosphatase Activity (pmoles/min)
HMVEC Treatment
Immunoprecipitate FGFR-1 1 Integrin
Control (untreated) 1.58  0.28 2.01 0.20
FGF-2 0.83  0.28* 2.35  0.32
FGF-2  TIMP-2 1.47  0.22 1.64  0.20*
FGF-2  AlaTIMP-2 1.63  0.73 1.68  0.25*
Immunoprecipitate KDR 1 Integrin
Control (untreated) 2.54  0.45 2.54  0.40
VEGF-A 1.42  0.49* 2.52  0.32
VEGF-A  TIMP-2 2.75  0.56 1.46  0.31*
VEGF-A  AlaTIMP-2 3.10  0.48 1.60  0.35*
* p  0.05 (compared with control)
of FGFR-1 and KDR activation, we examine total PTP
activity present in FGFR-1 or KDR complexes. FGFR-1
and KDR complexes were isolated by immunoprecipita-
tion following TIMP-2 treatment (15 min) followed by
brief (5 min) angiogenic factor stimulation. Measurement
of total PTP activity associated with the FGFR-1 or KDR
complexes demonstrates that TIMP-2 and AlaTIMP-2
induce a statistically significant increase in total PTP
activity associated with these RTK complexes when Figure 5. Effects of TIMP-2 and AlaTIMP-2 on Angiogenesis In
compared with angiogenic factor treatment alone (Table Vivo
1). Analysis of total PTP activity in 1 integrin immuno- (A) Directed in vivo angiogenesis assay (DIVAA) was performed to
precipitation experiments shows a concomitant de- determine effects of TIMP or AlaTIMP-2 on in vivo angiogenesis.
Control experiments indicate that neither TIMP-2 nor orthovanadatecrease in 1-associated PTP activity in hMVECs treated
(Vn) induce a significant angiogenic response compared to negativewith either TIMP-2 or AlaTIMP-2 (Table 1). These find-
control. FGF-2 or VEGF-A (each 500 ng/mL) induce significant angio-ings confirm the decrease in SHP-1 association with
genic responses that are suppressed (80% inhibition) by either
31 following TIMP-2 binding previously observed in TIMP-2 or AlaTIMP-2. The suppressive effects of both TIMP-2 and
immunoprecipitation experiments (Figure 3D), and dem- AlaTIMP-2 are reversed by inclusion of orthovanadate (Vn, 10 	M).
onstrate that along with decrease in SHP-1 association Statistical significance is indicated (* p  0.05).
(B) Dose-response of sodium orthovanadate on MMP-2 activity andwith 31 there is a concomitant increase in PTP activity
TIMP-2 anti-MMP activity. MMP-2 alone (); MMP inhibitor activityin association with RTKs, FGFR-1, and KDR, following
of TIMP-2 () and AlaTIMP-2 ().TIMP-2 or AlaTIMP-2 treatment.
Dominant-Negative SHP-1 Abrogates TIMP-2 tion and are unresponsive to the suppressive effect
Suppression of hMVEC Proliferation TIMP-2 on cell growth (Figure 4C). This finding implies
Several laboratories have successfully utilized expres- that SHP-1 activity is specifically required for the TIMP-
sion of dominant-negative SHP-1 to directly explore the 2-mediated effects on hMVEC proliferation.
role of SHP-1 in regulation of cell signaling (Bousquet
et al., 1998) and we adopted this strategy to study SHP-1
in hMVECs. Wild-type (wt) and dominant-negative (dn) TIMP-2 and AlaTIMP-2 Inhibit Angiogenesis
In Vivo via a PTP-Dependent MechanismSHP-1 replication-defective human adenoviruses (Ad5)
were used to infect hMVEC cultures. The expression of The biological significance of TIMP-2 inhibition of endo-
thelial cell proliferation is examined utilizing an in vivoSHP-1 protein, total cytoplasmic PTP activity, as well
as response to FGF-2 stimulation in the presence or angiogenesis assay. In these experiments we utilized the
quantitative directed in vivo angiogenesis assay (DIVAA)absence of TIMP-2 was monitored in these cultures.
SHP-1 expression and total PTP activity in hMVEC (Guedez et al., 2003). All data are obtained using a single,
FGF-2 or VEGF-A “angioreactor” implant per mouse,whole-cell lysates reveal increased immunoreactive
protein in both wt and dnSHP-1 transduced hMVECs. with experiments performed in quadruplicate. Results
from these in vivo angiogenesis assays show thatIn dnSHP-1 hMVECs, there is an increase in immunore-
active SHP-1 that is not associated with an increase TIMP-2 or orthovanadate do not significantly alter the
minimal response in angioreactors that do not containin total PTP activity, consistent with expression of an
inactive mutant PTP. Comparison of the TIMP-2 effects an angiogenic growth factor (Figure 5A). Both FGF-2
and VEGF-A generate a robust angiogenic response inon FGF-2-stimulated proliferation demonstrates that in
vector control and wtSHP-1 expressing hMVECs cell vivo (Figure 5A). TIMP-2 and AlaTIMP-2 (200 nM) are
equipotent in their ability to inhibit angiogenic responsesproliferation in response to FGF-2 is inhibited by TIMP-2,
identical to our previous observations (Figure 4C). How- to FGF-2 and VEGF-A in vivo. These results show that
TIMP-2 and AlaTIMP-2 possess potent inhibitory ac-ever, dnSHP-1 cells have a higher rate of basal prolifera-
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tivity (
80% inhibition) against both FGF-2- and VEGF- 3 chain, which binds to V3, suppresses endothelial
cell protein synthesis and FAK activation (Maeshima etA-induced angiogenic responses and that this effect is
al., 2002).independent of the anti-MMP activity as demonstrated
The role of 31 in angiogenesis is not well under-by AlaTIMP-2.
stood although this receptor is expressed on both quies-We next examine the role of PTP activity in the antian-
cent and activated endothelial cells (Stupack and Che-giogenic effect of TIMP-2 in vivo. Orthovanadate abro-
resh, 2002). This laminin binding integrin may participategates the antiproliferative effect of TIMP-2 and Ala
directly or indirectly (Wei et al., 2001) in cell migrationTIMP-2 on hMVECs in vitro. To conduct in vivo studies
on collagen, laminin, and fibronectin, but also acts aswith this PTP inhibitor, we first examine the effect of
a principal receptor for the angiogenesis inhibitor throm-orthovanadate directly on MMP activity and the ability
bospondin (Yanez-Mo et al., 1998). Our results showof TIMP-2 to inhibit MMP activity (Figure 5B). These in
direct binding of TIMP-2 to 31 and suggest that thisvitro experiments demonstrate that orthovanadate does
interaction initiates a signaling pathway involving PTPnot inhibit MMP activity or interfere with the ability of
inactivation of RTK stimulation. This interaction resultsTIMP-2 to inhibit MMP activity at orthovanadate concen-
in decreased association of HSP60 and SHP-1 withtrations as high as 50 	M. In vivo, orthovanadate did
31, suggesting that binding of TIMP-2 functionallynot alter the basal response (unstimulated) or the angio-
alters interaction of the 31 with these proteins. It hasgenic response to either FGF-2 or VEGF-A (Figure 5A).
been suggested that dissociation of HSP60 from 31However, inclusion of orthovanadate completely abol-
is coincident with integrin activation (Barazi et al., 2002).ishes the in vivo, antiangiogenic activity of TIMP-2 in
Our results appear consistent with this observation, inresponse to either FGF-2 or VEGF-A-induced angiogen-
that TIMP-2 interaction with 31 results in propagationesis (Figure 5A). These findings suggest that the antian-
of a signal (i.e., reduced SHP-1 association), but it isgiogenic effect of TIMP-2 and AlaTIMP-2 in vivo, like
also possible that TIMP-2 antagonizes the interactionthe in vitro inhibitory effect on hMVEC proliferation, is
of this integrin with another ECM ligand. TIMP-2 treat-principally mediated via PTP activity, putatively SHP-1.
ment of hMVEC did not alter the attachment or spreadingFurthermore, it is this orthovanadate-sensitive mecha-
of these cells to ECM components or induce apoptosisnism for TIMP-2 inhibition of hMVEC proliferation, not
in vitro (D.-W.S. and W.G.S.-S., unpublished data). Treat-MMP inhibition, which appears responsible for the sup-
ment of 1 null GD25 murine fibroblasts with TIMP-2pression of angiogenesis in vivo. This is evidenced by
failed to inhibit PDGF-stimulated proliferation of thesethe complete reversal of the TIMP-2 antiangiogenic ac-
cells, and reconstitution of 1 expression in GD25-1Ativity in the presence of orthovanadate, which does not
cells restored TIMP-2 responsiveness. Collectively,interfere with TIMP-2 anti-MMP activity.
these findings suggest that TIMP-2 does not function
as a simple antagonist of 31, but binding of TIMP-2Discussion
to this receptor results in altered signal transductionOur current study describes a mechanism in which a
leading to suppression of hMVEC proliferation.soluble extracellular matrix component, TIMP-2, and an
Further evidence for this mechanism derives from our
extracellular matrix receptor, 31, interact with a RTK,
experiments demonstrating that TIMP-2 suppresses
either FGFR-1 or KDR, to negatively regulate the mito-
FGFR-1 and KDR phosphorylation in response to treat-
genic response of hMVECs to angiogenic stimuli (FGF-2
ment with cognate ligands, FGF-2, and VEGF-A, respec-
or VEGF-A), in a PTP-dependent fashion. This response tively. This reduced RTK phosphorylation was sensitive
is specific to TIMP-2, but independent of MMP-inhibi- to the PTP inhibitor orthovanadate in both FGF-2- and
tory activity, as demonstrated through the use of VEGF-A-stimulated hMVECs. TIMP-2 binding to 31
AlaTIMP-2, a null-MMP-inhibitor form of TIMP-2. results in enhanced association of the PTP SHP-1 with
Based on previous findings, we proposed a cell sur- the RTKs, FGFR-1 and KDR, compared with angiogenic
face receptor mechanism for TIMP-2 that would mediate factor treatment alone. We have previously reported on
these selective effects on cell proliferation (Murphy et a similar mechanism in TIMP-2 suppression of EGFR
al., 1993). We demonstrate that TIMP-2 binding to signaling (Hoegy et al., 2001), and others have noted a
hMVECs is mediated by 31 integrin. This interaction requirement for SHP-1 activity in TNF- inhibition of
is confirmed by direct demonstration of preferential both VEGF-A and EGF stimulation of endothelial cells,
binding of TIMP-2 to31 in vitro, as well as immunopre- and this mechanism is often referred to as heterologous
cipitation experiments using anti-TIMP-2 antibodies. receptor inactivation (Guo et al., 2000).
Several angiogenesis inhibitors have been described The TIMP-2-induced association of SHP-1 with these
which appear to function as antagonists for ligand- RTKs is functionally relevant. TIMP-2 enhanced total
receptor interactions critical for angiogenesis. These in- PTP activity associated with either FGFR-1 or KDR when
clude TIMP-3 that antagonizes VEGF-A binding to KDR, compared to levels following stimulation with either an-
as well as endostatin and angiostatin, which antagonize giogenic factor alone. TIMP-2 reduces total PTP activity
interaction ofV3 with its ligands. These later inhibitors associated with the 31 under conditions where PTP
disrupt endothelial cell attachment and migration, re- activity in the FGFR-1 or KDR complexes is increased.
sulting in endothelial cell apoptosis (Rehn et al., 2001; These findings, combined with the data showing de-
Tarui et al., 2001). In contrast to angiogenesis inhibitors creased SHP-1 association with 31 immunoprecipi-
that function as antagonists, few angiogenesis inhibitors tates following TIMP-2 treatment, lead us to speculate
appear to initiate signaling pathways following integrin that TIMP-2 may induce a transfer, either direct or indi-
binding. A possible example of this latter mechanism is rect, of SHP-1 activity from 31 to either FGFR-1 or KDR.
SHP-1 is expressed in a variety of cell types includingtumstatin, a fragment of the NC1 domain of collagen IV
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hematopoietic cells, epithelial cells, and endothelial giogenic therapies, in addition to synthetic metallopro-
cells (Nakagami et al., 2002; Keilhack et al., 1998). Sev- teinase inhibitors (Coussens et al., 2002).
eral reports confirm that overexpression of catalytically In summary, data presented in this report demonstrate
inactive (dominant-negative) SHP-1 results in sustained that TIMP-2 and AlaTIMP-2 potently inhibit endothelial
mitogenic signaling (Bousquet et al., 1998). In endothe- cell proliferation in response to FGF-2 or VEGF-A stimu-
lial cells SHP-1 activation by TNF- reportedly inhibits lation in vitro. In vivo TIMP-2 and AlaTIMP-2 both func-
VEGF- and EGF-proliferative responses, and expression tion to potently inhibit angiogenic responses induced
of dnSHP-1 prevented the inhibitory effect of TNF- by either FGF-2 or VEGF-A. The suppressive effect of
on endothelial cell proliferation (Nakagami et al., 2002). TIMP-2 on hMVEC proliferation in vitro is reversed in 1
Similarly, we show that expression of dnSHP-1 in hMVEC null murine embryo fibroblasts and in hMVECs express-
results in enhanced basal proliferation and abrogates ing dnSHP-1, directly implicating both 31 and SHP-1
the suppressive effects of TIMP-2 cell proliferation. as mediators of TIMP-2 repression of hMVEC mitogenic
These findings corroborate the observed increase in stimulation. Since both the in vitro and in vivo effects
SHP-1 and elevated total PTP activity associated with are abrogated by the PTP inhibitor orthovanadate, we
the FGFR-1 and KDR complexes following TIMP-2 treat- propose that TIMP-2-induced SHP-1-mediated inacti-
ment. Collectively, these findings implicate a direct role vation of RTKs or other downstream effectors, not anti-
for SHP-1 in mediating the suppressive effects of MMP activity, is responsible for both effects. This is an
TIMP-2 on hMVEC mitogenic responses. unexpected mechanism of action for TIMP-2 inhibition
Several reports have shown that TIMPs can inhibit of angiogenesis in that it has long been presumed that
angiogenic responses in vitro (Jiang et al., 2002; Murphy the principal antiangiogenic effects of all TIMPs were
et al., 1993). In addition, TIMPs have been shown to exclusively due to inhibition of MMP activity. The sup-
reduce tumor growth and vascularity in vivo (Guedez et pressive effect of TIMP-2 on angiogenesis is mediated
al., 2001b; Imren et al., 1996). However, the mechanism by PTP activity (blocked by orthovanadate), suggesting
of these effects has been presumed to involve indirect that selective manipulation of SHP-1 activity in endothe-
suppression of angiogenesis through inhibition of MMP lial cells may be a target for therapeutic intervention in
activity required for endothelial cell migration and/or a variety pathologic conditions associated with angio-
invasion. In our study, TIMP-2 inhibited in vivo angio- genic responses. Finally, the development of synthetic
genic responses to both FGF-2 and VEGF-A in an MMP- metalloproteinase inhibitors for clinical trials in cancer
independent orthovanadate-sensitive fashion. This find- therapy was based, at least in part, on the observation
ing indicates that the mechanism for TIMP-2 inhibition that TIMP-2 inhibits tumor growth in animal models
of angiogenesis in vivo is functionally similar to that (Coussens et al., 2002). Our present findings may par-
involved in inhibition of hMVEC proliferation in vitro. In tially explain the failure of these synthetic MMP inhibi-
addition, orthovanadate did not inhibit MMP activity or tors in these clinical trials.
interfere with TIMP-2 inhibition of MMP activity sug-
gesting that in our in vivo angiogenesis assays the MMP Experimental Procedures
inhibitory activity of TIMP-2 is not compromised.
Cell Lines, Growth Factors, and AntibodiesIt is surprising to observe that orthovanadate com-
Human microvascular endothelial cells (Clonetics) were grown inpletely reversed the inhibitory effect of TIMP-2 on angio-
EGM-2 MV BulletKit medium. GD25 1 null murine embryonic fibro-genesis in vivo, considering the long-standing assump-
blasts and GD25-1A cells were a kind gift from D.F. Mosher (Univer-
tion that TIMPs function principally through inhibition of sity of Wisconsin). Growth factors (FGF-2, VEGF-A, and PDGF-BB)
MMP activity. Our findings demonstrate that TIMP-2 were obtained from commercial sources, stored, and reconstituted
inhibition of angiogenesis in vivo shares two characteris- according to the manufacturer’s instructions. Commercial primary
antibodies were antiphosphotyrosine, anti-PTP1C/SHP-1, anti-1tics with the in vitro mechanism of endothelial cell
(clone 18), anti-3 (clone 1), and anti-V (clone 21) (BD Transductiongrowth inhibition. These include independence from
Laboratories); anti-1 (clone Ha31/8), anti-1 (clone Ha2/5), anti-MMP inhibition (AlaTIMP-2 is antiangiogenic in vivo)
4 (clone 9C10), anti-5 (clone 5H10-27) (BD Pharmingen); anti-1and both are sensitive to the PTP inhibitor orthovana-
(FB12), anti-3 (P1B5), anti-3 (ASC-1), anti-1 (clone LM534), anti-
date. Thus, the spectrum of physiologic activities of 4 (P1H4), anti-5 (polyclonal), anti-3 (clone 25E11), anti-3 (B3A),
TIMP-2 in vivo involves both MMP inhibitor functions, anti-4 (clone ASC-3), anti-4 (ASC-8) and anti-MT1-MMP (clone
as well as MMP-independent activities, such as growth 114-6G6) (Chemicon); anti-FGFR-1, anti-VEGFR-2 (anti-KDR), anti-
HSP60 and anti-3 (polyclonal) (Santa Cruz Biotechnology); andsuppression. Our in vitro results demonstrate that TIMP-2
anti-VEGFR-2 (R & D Systems, competition assays). Murine andbinds to 31 and initiates a signaling cascade that
rabbit IgG-horseradish peroxidase conjugates were used as sec-results in enhanced PTP activity associated with angio-
ondary antibodies for enhanced chemiluminescence detectiongenic factor receptors. Although our data suggest that
(Santa Cruz Biotechnology).
TIMP-2 inhibition of endothelial cell proliferation is an Recombinant TIMP-2, AlaTIMP-2, and AlaTIMP-1 were pre-
important component of the TIMP-2 antiangiogenic ef- pared as described (Wingfield et al., 1999), and endotoxin tested
fect, downstream effects in this TIMP-2 signaling cas- using the Limulus amoebocyte lysis (2 EU/mg protein).
cade (that would also be orthovanadate sensitive) may
Cell Growth Assaysalso be required for inhibition of angiogenesis. The ef-
HMVECs, plated on 96-well plates (5  103 cells/well) were grownfects of TIMP-2 on additional endothelial cell functions
in basal medium, EBM-2 without serum or growth factors, for 24 hrrequired for angiogenesis, such as effects on cell sur-
to allow synchronization of cells in G1/G0 prior to treatment withvival, invasion, and/or differentiation, remain to be deter- TIMP-2 or AlaTIMP-2 (50 nM). Following subsequent growth factor
mined in vivo. This description of TIMP-2-mediated mi- stimulation and culture, the cell numbers were quantified using Cell-
togenic suppression of endothelial cell growth suggests Titer 96 AQueous One Solution reagent (Promega) according to the
manufacturer’s directions. The results from triplicate determinationspossible new strategies for the development of antian-
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(mean  standard deviation) are presented as the fold-increase of QBI-293A cells and subsequent plaques were selected and ampli-
fied. Expression of wt and dn SHP-1 in adenovirus infected cellsnonstimulated growth or the percentage of maximal FGF-2 (50 ng/
mL)- or VEGF-A (10 ng/mL)-stimulated growth to allow comparison were verified by Western blotting using anti-PTP1C/SHP1 antibody
(Transduction Laboratories) and PTP assay of whole-cell lysates.between experiments.
Adenovirus (Adv-vector) without an expression cassette was used
as control (vector).Competitive Binding Assays
TIMP-2 and AlaTIMP-2 were labeled with 125I-Na using IODO Beads
Metalloproteinase Assaysiodination reagent (Pierce, Rockford, IL) according to the manufac-
The effect of sodium orthovanadate on MMP-2 and TIMP-2 anti-turer’s instructions. hMVEC monolayers were serum starved for 1 hr
MMP activity was determined in vitro using colorimetric assay asand twice washed with ice-cold PBS, pretreated for 20 min with
previously described (Hoegy et al., 2001; Wingfield et al., 1999).blocking antibodies or unlabeled TIMP-2 or AlaTIMP-2, and incu-
bated with the indicated concentrations of 125I-TIMP-2 or 125I-Ala
TIMP-2 for 2 hr at 4C. Binding of 125I-labeled TIMPs to the cells was Directed In Vivo Angiogenesis Assays
determined by  counting (dpm) on a Packard, Cobra auto--counter Quantification of the angiogenic responses was performed utilizing
(Canberra Company). the directed in vivo angiogenesis assay (DIVAA) as previously de-
scribed (Guedez et al., 2003).
FGF-2 Dimer Formation Assay
Analysis of FGF-2 dimerization was performed as described (Perollet Statistical Analysis
et al., 1998). Dimer formation was quantified by autoradiography. Experimental results were analyzed for statistical significance (Stu-
dent’s t test) or curve-fit analysis using Prism Software package
(GraphPad). Results presented are representative of at least dupli-Integrin-Blocking Antibody Competition
cate experiments, and statistical significance is indicated (* p Binding Experiments
0.05; ** p  0.01).hMVEC monolayers were serum starved for 2 hr and twice washed
with ice-cold PBS, pretreated with anti-integrin function blocking
antibodies (20 	g/ml) in binding buffer containing Hanks’ balanced Acknowledgments
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